ArticleTranslational cancer research2020
Nomogram for predicting axillary lymph node status after neoadjuvant chemotherapy in breast cancer.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Development and internal validation of a nomogram for predicting neoadjuvant therapy efficacy in breast cancer based on the HALP score.Translational cancer research · 2026Article
- A novel nomogram model of breast cancer-based imaging for predicting the status of axillary lymph nodes after neoadjuvant therapy.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany breast cancer patients benefit from neoadjuvant chemotherapy (NAC). However, sentinel lymph node biopsy (SLNB) after NAC remains controversial, especially for patients with axillary lymph node metastasis (ALNM) at diagnosis. We developed a nomogram for predicting axillary lymph node (ALN) status after NAC to screen for patients for whom SLNB may be beneficial.
methodsA total of 320 cT1-4N0-1M0 breast cancer patients receiving ALN dissection (ALND) after NAC were included. Univariate and multivariate logistic regression analyses determined significant factors for predicting ALN status. Efficacy of the resulting nomogram was assessed using receiver operating characteristic (ROC) and calibration curves, while decision curve analysis (DCA) was used to evaluated net clinical benefit. Our nomogram was validated using female patients grouped according to a diagnosis of node-positive (cN1) or node-negative (cN0) by ultrasound-guided needle biopsy of suspected lymph nodes before NAC.
resultsLogistic regression analyses indicated that estrogen receptor (ER), Ki67, degree of tumor regression, clinical tumor T stage after NAC, and ALN Breast Imagining-Reporting and Data System (BI-RADS) category after NAC, were associated with ALN status. The resulting nomogram had an area under the curve (AUC) of 0.802 [95% confidence interval (CI), 0.7485-0.8554], and the calibration plot showed strong uniformity between predicted and actual ALN status. DCA indicated a positive net benefit of nomogram predictions in our cohort. After internal validation, the cN1 and cN0 groups had an AUC of 0.7926 (95% CI, 0.7187-0.8665) and 0.8165 (95% CI, 0.7381-0.8949), respectively. The calibration plot indicated better performance in the cN0 group.
conclusionsAfter NAC, some patients may benefit from SLNB. Our nomogram predicts ALN status after NAC and has great potential to assist in clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.